Journal Of Clinical Oncology Publishes Data On BLINCYTO® (Blinatumomab) In High-Risk Patients With Philadelphia Chromosome-Positive B-Cell Precursor Acute Lymphoblastic Leukemia

BLINCYTO is the Only Bispecific T Cell Engager (BiTE®) Immunotherapy Approved in the U.S.Complete Remission or Complete Remission With Partial Hematologic Recovery was Induced in More Than 35 Percent of Patients

Amgen - Investors - RSS Content